guest ::
| Home > Publications Database > The status of the terminal regions of α-synuclein in different forms of aggregates during fibrillization > print |
| Home > Publications Database > The status of the terminal regions of α-synuclein in different forms of aggregates during fibrillization > print |
| 001 | 151598 | ||
| 005 | 20230915094003.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ijbiomac.2020.03.238 |2 doi |
| 024 | 7 | _ | |a 0141-8130 |2 ISSN |
| 024 | 7 | _ | |a 1879-0003 |2 ISSN |
| 024 | 7 | _ | |a altmetric:78957872 |2 altmetric |
| 024 | 7 | _ | |a pmid:32240735 |2 pmid |
| 037 | _ | _ | |a DZNE-2020-01182 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Tayaranian Marvian, Amir |0 P:(DE-2719)9000203 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a The status of the terminal regions of α-synuclein in different forms of aggregates during fibrillization |
| 260 | _ | _ | |a New York, NY [u.a.] |c 2020 |b Elsevier |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2020-07-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1685012533_32152 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The α-synuclein (αSN) amyloid fibrillization process is known to be a crucial phenomenon associated with neuronal loss in various neurodegenerative diseases, most famously Parkinson's disease. The process involves different aggregated species and ultimately leads to formation of β-sheet rich fibrillar structures. Despite the essential role of αSN aggregation in the pathoetiology of various neurological disorders, the characteristics of various assemblies are not fully understood. Here, we established a fluorescence-based model for studying the end-parts of αSN to decipher the structural aspects of aggregates during the fibrillization. Our model proved highly sensitive to the events at the early stage of the fibrillization process, which are hardly detectable with routine techniques. Combining fluorescent and PAGE analysis, we found different oligomeric aggregates in the nucleation phase of fibrillization with different sensitivity to SDS and different structures based on αSN termini. Moreover, we found that these oligomers are highly dynamic: after reaching peak levels during fibrillization, they decline and eventually disappear, suggesting their transformation into other αSN aggregated species. These findings shed light on the structural features of various αSN aggregates and their dynamics in synucleinopathies. |
| 536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
| 542 | _ | _ | |i 2020-07-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 542 | _ | _ | |i 2020-04-11 |2 Crossref |u http://creativecommons.org/licenses/by/4.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 650 | _ | 2 | |a Amyloid: chemistry |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Mutant Proteins: chemistry |2 MeSH |
| 650 | _ | 2 | |a Mutant Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Mutant Proteins: metabolism |2 MeSH |
| 650 | _ | 2 | |a Mutation |2 MeSH |
| 650 | _ | 2 | |a Protein Interaction Domains and Motifs |2 MeSH |
| 650 | _ | 2 | |a Protein Multimerization |2 MeSH |
| 650 | _ | 2 | |a alpha-Synuclein: chemistry |2 MeSH |
| 650 | _ | 2 | |a alpha-Synuclein: genetics |2 MeSH |
| 650 | _ | 2 | |a alpha-Synuclein: metabolism |2 MeSH |
| 700 | 1 | _ | |a Aliakbari, Farhang |b 1 |
| 700 | 1 | _ | |a Mohammad-Beigi, Hossein |b 2 |
| 700 | 1 | _ | |a Ahmadi, Zeinab Alsadat |b 3 |
| 700 | 1 | _ | |a Mehrpooyan, Sina |b 4 |
| 700 | 1 | _ | |a Lermyte, Frederik |b 5 |
| 700 | 1 | _ | |a Nasouti, Mahour |b 6 |
| 700 | 1 | _ | |a Collingwood, Joanna F. |b 7 |
| 700 | 1 | _ | |a Otzen, Daniel E. |b 8 |
| 700 | 1 | _ | |a Morshedi, Dina |0 P:(DE-HGF)0 |b 9 |e Corresponding author |
| 773 | 1 | 8 | |a 10.1016/j.ijbiomac.2020.03.238 |b : Elsevier BV, 2020-07-01 |p 543-550 |3 journal-article |2 Crossref |t International Journal of Biological Macromolecules |v 155 |y 2020 |x 0141-8130 |
| 773 | _ | _ | |a 10.1016/j.ijbiomac.2020.03.238 |g Vol. 155, p. 543 - 550 |0 PERI:(DE-600)1483284-7 |p 543-550 |t International journal of biological macromolecules |v 155 |y 2020 |x 0141-8130 |
| 856 | 4 | _ | |u https://www.sciencedirect.com/science/article/pii/S0141813020328257 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/151598/files/DZNE-2020-01182.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/151598/files/DZNE-2020-01182.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:151598 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)9000203 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-01-15 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-25 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-25 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J BIOL MACROMOL : 2021 |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-25 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J BIOL MACROMOL : 2021 |d 2022-11-25 |
| 920 | 1 | _ | |0 I:(DE-2719)1110002 |k AG Höglinger 1 ; AG Höglinger 1 |l Translational Neurodegeneration |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1110002 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|